Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Aminocaproic Acid, Bleeding Complications Assessed

Leuk Lymphoma; ePub 2018 Feb 9; Juhl, Roddy, et al

Aminocaproic acid does not seem to lead to a high incidence of thromboembolic complications in people with hematologic malignancies, researchers concluded after conducting a retrospective study involving 109 individuals. Participants with hematologic malignancies had received aminocaproic acid to prevent/treat of thrombocytopenic hemorrhage. Investigators looked for thromboembolic complications confirmed by imaging studies. Among the results:

  • 5% of patients experienced thromboembolic complications; all were venous thromboses.
  • These patients had additional risk factors, such as central venous catheters.

The author noted that the concurrent risk factors may have played a role in thromboses.


Juhl R, Roddy J, Wang T, Li J, Elefritz J. Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. [Published online ahead of print February 9, 2018]. Leuk Lymphoma. doi:10.1080/10428194.2018.1434882.